Inhibition of mycobacterial alanine racemase activity and growth by thiadiazolidinones

Biochemical Pharmacology

Volumn 86, Issue 2, 2013, Pages 222-230

  Lee, Yashang ^a   Mootien, Sara ^a   Shoen, Carolyn ^b   Destefano, Michelle ^b   Cirillo, Pier ^a   Asojo, Oluwatoyin A ^c   Yeung, Kacheong R ^a   Ledizet, Michel ^a   Cynamon, Michael H ^b   Aristoff, Paul A ^a   Koski, Raymond A ^a   Kaplan, Paul A ^a   Anthony, Karen G ^a  

^a L2 Diagnostics LLC   (United States)

^b SYRACUSE VA MEDICAL CENTER   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Alanine racemase; D alanine; Mycobacterium smegmatis; Mycobacterium tuberculosis; Thiadiazolidinones

Indexed keywords

ALANINE RACEMASE; ANTIMYCOBACTERIAL AGENT; CYCLOSERINE; HETEROCYCLIC COMPOUND; THIADIAZOLIDINONE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; DRUG CYTOTOXICITY; ELECTROSPRAY MASS SPECTROMETRY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PURIFICATION; FEMALE; HELA CELL; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IC 50; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR CLONING; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 84884901541     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2013.05.004     Document Type: Article

References (39)

1. Shinnick TM, Good RC. Mycobacterial taxonomy. Eur J Clin Microbiol Infect Dis 1994;13:884-901.
2. Howard ST, Byrd TF. The rapidly growing mycobacteria: saprophytes and parasites. Microbes Infect 2000;2:1845-53. (Pubitemid 32063538)
3. Organization WH. Tuberculosis WHO Global Tuberculosis Report 2012. Geneva: World Health Organization; 2012 , http://wwwwhoint/tb/publications/ factsheets/en/indexhtml.
4. Brennan PJ, Crick DC. The cell-wall core of Mycobacterium tuberculosis in the context of drug discovery. Curr Top Med Chem 2007;7:475-88. (Pubitemid 46488288)
5. Ginsberg A, Spigelman M. Challenges in tuberculosis drug research and development. Nat Med 2007;13:290-4. (Pubitemid 46376672)
6. Wright A, Zignol M, Van Deun A, Falzon D, Gerdes SR, Feldman K, et al. Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Lancet 2009;373:1861-73.
7. Osborne R. First novel anti-tuberculosis drug in 40 years. Nat Biotechnol 2013;31:89-91.
8. Diacon AH, Donald PR, Pym A, Grobusch M, Patientia RF, Mahanyele R, et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother 2012;56: 3271-6.
9. Yew WW, Leung CC. Management of multidrug-resistant tuberculosis: update 2007. Respirology 2008;13:21-46.
10. Grosset JH, Singer TG, Bishai WR. New drugs for the treatment of tuberculosis: hope and reality. Int J Tuberc Lung Dis 2012;16:1005-14.
11. Copie V, Faraci WS, Walsh CT, Griffin RG. Inhibition of alanine racemase by alanine phosphonate: detection of an imine linkage to pyridoxal 50-phosphate in the enzyme-inhibitor complex by solid-state 15N nuclear magnetic resonance. Biochemistry 1988;27:4966-70.
12. Lambert MP, Neuhaus FC. Mechanism of D-cycloserine action: alanine racemase from Escherichia coli W. J Bacteriol 1972;110:978-87.
13. Silverman RB. The potential use of mechanism-based enzyme inactivators in medicine. J Enzyme Inhib 1988;2:73-90. (Pubitemid 18033735)
14. Walsh CT. Enzymes in the D-alanine branch of bacterial cell wall peptidoglycan assembly. J Biol Chem 1989;264:2393-6. (Pubitemid 19057720)
15. Milligan DL, Tran SL, Strych U, Cook GM, Krause KL. The alanine racemase of Mycobacterium smegmatis is essential for growth in the absence of D-alanine. J Bacteriol 2007;189:8381-6. (Pubitemid 350178954)
16. Sassetti CM, Boyd DH, Rubin EJ. Genes required for mycobacterial growth defined by high density mutagenesis. Mol Microbiol 2003;48:77-84. (Pubitemid 36411469)
17. Awasthy D, Bharath S, Subbulakshmi V, Sharma U. Alanine racemase mutants of Mycobacterium tuberculosis require D-alanine for growth and are defective for survival in macrophages and mice. Microbiology 2012;158:319-27.
18. Noda M, Matoba Y, Kumagai T, Sugiyama M. Structural evidence that alanine racemase from a D-cycloserine-producing microorganism exhibits resistance to its own product. J Biol Chem 2004;279:46153-61. (Pubitemid 39491610)
19. Newton RW. Side effects of drugs used to treat tuberculosis. Scott Med J 1975;20:47-9.
20. Yew WW, Wong CF, Wong PC, Lee J, Chau CH. Adverse neurological reactions in patients with multidrug-resistant pulmonary tuberculosis after coadministration of cycloserine and ofloxacin. Clin Infect Dis 1993;17:288-9. (Pubitemid 23228475)
21. Snavely SR, Hodges GR. The neurotoxicity of antibacterial agents. Ann Intern Med 1984;101:92-104. (Pubitemid 14088076)
22. Fenn TD, Stamper GF, Morollo AA, Ringe D. A side reaction of alanine racemase: transamination of cycloserine. Biochemistry 2003;42:5775-83. (Pubitemid 36582869)
23. Anthony KG, Strych U, Yeung KR, Shoen CS, Perez O, Krause KL, et al. New classes of alanine racemase inhibitors identified by high-throughput screening show antimicrobial activity against Mycobacterium tuberculosis. PLoS One 2011;6:e20374.
24. Ciustea M, Mootien S, Rosato AE, Perez O, Cirillo P, Yeung KR, et al. Thiadiazolidinones: a new class of alanine racemase inhibitors with antimicrobial activity against methicillin-resistant Staphylococcus aureus. Biochem Pharmacol 2012;83:368-77.
25. Strych U, Penland RL, Jimenez M, Krause KL, Benedik MJ. Characterization of the alanine racemases from two mycobacteria. FEMS Microbiol Lett 2001;196: 93-8. (Pubitemid 32232243)
26. http://genome.tbdb.org/annotation/genome/tbdb/GenomeDescriptions. html#MT-Smeg.
27. http://genome.tbdb.org/annotation/genome/tbdb/GenomeDescriptions. html#Mycobacterium-tuberculosis-H37Rv.
28. LeMagueres P, Im H, Ebalunode J, Strych U, Benedik MJ, Briggs JM, et al. The 1.9 A crystal structure of alanine racemase from Mycobacterium tuberculosis contains a conserved entryway into the active site. Biochemistry 2005;44: 1471-81. (Pubitemid 40204391)
29. Marcinkeviciene J, Rogers MJ, Kopcho L, Jiang W, Wang K, Murphy DJ, et al. Selective inhibition of bacterial dihydroorotate dehydrogenases by thiadiazolidinediones. Biochem Pharmacol 2000;60:339-42. (Pubitemid 30336630)
30. Wasserman SA, Walsh CT, Botstein D. Two alanine racemase genes in Salmonella typhimurium that differ in structure and function. J Bacteriol 1983;153: 1439-50. (Pubitemid 13127833)
31. Badet B, Roise D, Walsh CT. Inactivation of the dadB Salmonella typhimurium alanine racemase by D and L isomers of beta-substituted alanines: kinetics, stoichiometry, active site peptide sequencing, and reaction mechanism. Biochemistry 1984;23:5188-94.
32. Wild J, Hennig J, Lobocka M, Walczak W, Klopotowski T. Identification of the dadX gene coding for the predominant isozyme of alanine racemase in Escherichia coli K12. Mol Gen Genet 1985;198:315-22. (Pubitemid 15141833)
33. Strych U, Huang HC, Krause KL, Benedik MJ. Characterization of the alanine racemases from Pseudomonas aeruginosa PAO1. Curr Microbiol 2000;41: 290-4.
34. Ju J, Xu S, Furukawa Y, Zhang Y, Misono H, Minamino T, et al. Correlation between catalytic activity and monomer-dimer equilibrium of bacterial alanine racemases. J Biochem 2011;149:83-9.
35. Reyrat JM, Kahn D. Mycobacterium smegmatis: an absurd model for tuberculosis? Trends Microbiol 2001;9:472-4. (Pubitemid 32939352)
36. Ganapathi R.R., Robins R.K. 1,2,4-Thiadiazolidine-3.5-dione. USA 1978.
37. Heuer L, Wachtler P, Kugler M. Thiazole antiviral agents. 1995.
38. Hilleringmann M, Pansegrau W, Doyle M, Kaufman S, MacKichan ML, Gianfaldoni C, et al. Inhibitors of Helicobacter pylori ATPase Cagalpha block CagA transport and cag virulence. Microbiology 2006;152:2919-30. (Pubitemid 44542373)
39. Blazer LL, Zhang H, Casey EM, Husbands SM, Neubig RR. A nanomolar-potency small molecule inhibitor of regulator of G-protein signaling proteins. Biochemistry 2011;50:3181-92.